Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

NCT ID: NCT00420732

Last Updated: 2020-05-28

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2014-12-31

Brief Summary

To determine the response rate of the administration of HyperAcute-Lung Cancer Vaccine for subjects with stage IIIB or stage IV non-small cell lung cancer who have been treated with first line platinum-doublet therapy and have responded or are considered to have stable disease.

Detailed Description

Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with advanced stage lung cancer continue to die from their disease. Reasons for this include that: 1) patients are often diagnosed at a time when their lung cancer has already spread to other sites such as the chest cavity, bone, lung, liver, and brain limiting the options for local radiation therapy and surgery, and 2) the cancer cells are resistant or become resistant to chemotherapy drugs used to treat the patient. Resistance to one type of chemotherapy agent often rapidly leads to resistance against many other chemotherapy drugs.

These reasons are the major causes of cancer progression that are usually discussed when considering treatment options for patients with disease that continues to grow and spread. However, another important part of the body should be considered-- the immune system. Scientists have clearly shown that lung cancer cells produce a number of abnormal proteins or abnormal amounts of certain proteins found in normal lung cells. Normally one would expect a patient to develop an immune response against these abnormal proteins found in their cancer and attack them much the way we would fight off an infection from a foreign bacteria or virus. However, for reasons that scientists do not fully understand, the immune system fails to respond to these abnormal proteins and does not attack the lung cancer cells. This human clinical trial proposes a new way to make the immune system recognize the cancer and encourage it to attack the cancer cells.

Many people are familiar with the idea of transplants between people of organs like the kidneys or heart. When an organ transplant between two people is completed one of the problems that can occur is rejection of the donated organ by the recipient. This can occur because the immune system of the patient who receives the organ attacks the donated organ. If you were to attempt to transplant a pig heart to a human the rejection would be dramatically stronger than when organs are transplanted between two people. This is partly because lower animals express sugar-protein patterns on the surface of their cells that humans do not. In fact, our immune systems can quickly recognize tissues from lower mammals such as the pig or the mouse and destroys them.

In this project, we have put a mouse gene into human lung cancer cells that produces these abnormal sugar patterns and stimulates the immune system to attack the lung cancer. This strategy works well to kill human other cancer cells in the laboratory, but it needs to be tried in lung cancer patients to see if it will be effective and to determine if such a treatment causes any side effects. We propose to test this new treatment in subjects with non-small cell lung cancer to see if it can stop, slow or destroy tumors in these subjects. Subjects will be injected with an anti-tumor vaccine consisting of a mixture of three types of dead human lung cancer cells that have been genetically altered to express the mouse gene responsible for making this abnormal sugar-protein on the cells.

Conditions

Carcinoma, Non-Small-Cell Lung

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vaccine Group

Group Type: EXPERIMENTAL

HyperAcute-Lung Cancer Vaccine

Intervention Type: BIOLOGICAL

300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations

Interventions

HyperAcute-Lung Cancer Vaccine

300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations

Intervention Type: BIOLOGICAL

Other Intervention Names

HAL-1, HAL-2, HAL-3

Eligibility Criteria

Inclusion Criteria

• histological diagnosis of non-small cell lung cancer. Squamous cell (epidermoid), adenocarcinoma, bronchoalveolar carcinoma and large cell anaplastic lung carcinoma histologies are eligible. Mixed NSCLC/small cell, and variant large and small are not eligible.
• AJCC Stage IIIB(pleural effusion) or Stage IV NSCLC
• Subjects must have been previously treated with only a first line platinum-doublet therapy that may or may not include Avastin(R). Those treated with definitive chemo-radiation with curative or palliative intent or who have received multiple regimens are not eligible.
• Subjects' NSCLC must have responded or remained stable through first line platinum-doublet therapy.
• ECOG Performance Status ≤ 2.
• Serum albumin ≥ 3.0 gm/dL.
• Expected survival ≥ 6 months.
• Hemoglobin ≥ 9.0 g/dl
• Platelets ≥ 100,000 cells/mm3
• ANC ≥ 1500 cells/mm3
• Serum total bilirubin ≤ 2 x ULN, ALT and AST ≤ 2.5 x ULN (≤5 if hepatic metastasis is present).
• Serum creatinine ≤ 1.5 x ULN, or creatinine clearance ≥ 50 ml/min.
• Measurable or non-measurable disease.
• Subjects must have negative serology for HIV prior to entering study.
• Male and female subjects of child bearing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving experimental drug, and for one month after the last immunization.

Exclusion Criteria

• Age < 18 years.
• Active CNS metastases or carcinomatous meningitis.
• Subjects' whose NSCLC progressed during/after first line platinum-doublet therapy.
• Subjects having undergone splenectomy.
• Hypercalcemia > 2.9 mmol/L, unresponsive to standard therapy.
• Pregnant or nursing women.
• Other malignancy within the last 5 years, unless the probability of recurrence of the prior malignancy is < 30%. Patient's curatively treated for squamous and basal cell carcinoma of the skin and carcinoma in situ of the uterine cervix (CIN) or subjects with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.
• History of organ transplant.
• Current, active treatment with immunosuppressive therapy such as cyclosporine, tacrolimus, etc.
• Subjects taking systemic corticosteroid therapy for any reason including replacement therapy for hypoadrenalism, are not eligible. Subjects receiving inhaled or topical corticosteroids are eligible.
• Significant or uncontrolled congestive heart failure, myocardial infarction, significant ventricular arrhythmias within the last six months or significant pulmonary dysfunction.
• Active infection or antibiotics within 1-week prior to study, including unexplained fever.
• Autoimmune disease.
• Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study.
• A known allergy to any component of the vaccine.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

NewLink Genetics Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Charles J. Link, Jr., M.D.

Role: STUDY_CHAIR

NewLink Genetics Corporation

Locations

Northwestern University

Chicago, Illinois, United States

Washington University in St. Louis

St Louis, Missouri, United States

Countries

United States

Other Identifiers

OBA#0611-820

Identifier Type: OTHER

Identifier Source: secondary_id

NLG0201

Identifier Type: -

Identifier Source: org_study_id